CLINICAL STUDY OF CEFODIZIME

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement5; pp. 481 - 486
• Main Authors: MIKI, FUMIO, IKUNO, YOSHIYASU, INOUE, EIJI, MURATA, AKIHITO, TANIZAWA, SHINICHI, SAKAMOTO, KAZUO, TAHARA, AKIRA, KAWASE, YOSHIO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1988
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement5_481

Cefodizime, a new cephem antibiotic, was administered to patients with various infections, and the efficacy and safety of this drug were investigated. The following results were obtained. Cefodizime was administered by i.v. drip infusion to a total of 13 patients: 1 case of septicemia. 1 of meningitis, 7 of pneumonia, 2 of infected bronchiectasis, 1 of infected lung cancer and 1 of pyelonephritis. The dosage was 1 g per dose (2 g for septicemia), twice a day, for 6.5-28.5 days. Clinical efficacy in the 10 RTI cases was assessed as excellent in 1, good in 7 and fair in 2. The septicemia case was assessed as poor, the meningitis as good and the pyelonephritis case as good. Delayed disappearance of the infiltration in the chest X- ray was noteworthy in cases of pneumonia where clinical efficacy was evaluated as good based on normalized body temperature, improved inflammatory response, etc. Bacteriologically, 1 strain of P. rnirabilis persisted in septicemia, 1 each of S. pneumoniae, H. influenzae, and of K. pneumoniae were eradicated while another of K. pneumoniae persisted in the respiratory infection cases. No subjective or objective adverse reactions were observed. As abnormal laboratory findings, eosinophilia in 1, and elevated GOT and GPT in 2 cases were noted.